Список литературы

1. Смулевич А.Б. Расстройства личности. Рациональная фармакотерапия в психиатрической практике. Руководство для практикующих врачей. - М.: Литтера, 2014. - С. 458 - 493.

2. Смулевич А.Б. Расстройства личности. Психиатрия. Национальное руководство. - М.: ГЭОТАР-Медиа, 2018. - С. 663 - 668.

3. Рубинштейн С.Я. Экспериментальные методики патопсихологии и опыт применения их в клинике. - М.: Изд. Института психотерапии. 2010. - 414 с.

4. Linehan M.M., Amstrong H.E., Suarez A, Allmon D, Heard H.L. 1991. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 48: 1060 - 1064.

5. Linehan M.M., Tutek D.A., Heard H.L., Armstrong H.E. 1994. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. Am J Psychiatry 151: 1771 - 1776.

6. Linehan M.M. Schmidt H. 3rd, Dimeff L.A., Craft J.C., Kanter J. Comtois K.A. 1999. Dialectical behavior therapy for patients with borderline personality disorder and drugdependence. Am J Addict 8: 279 - 292.

7. Linehan M.M., Dimeff L.A., Reynolds S.K., et al. 2002. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend 67: 1326.

8. Linehan M.M., Comtois K.A., Murray A.M., et al. 2006. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 63: 757 - 766.

9. Verheul R, Van Den Bosch L.M., Koeter M.W., De Ridder M.A., Stijnen T., Van Den Brink W. 2003. Dialectical behavior therapy for women with borderline personality disorder: 12-month, randomised clinical trial in the netherlands. Br J Psychiatry 182: 135 - 140.

10. Bosch L.M., Koeter M.W., Stijnen T., Verheul R., van den Brink W. 2005. Substained efficacy of dialectical behavior therapy for borderline personality disorder. Behav Res Ther 43: 1231 - 1241.

11. Bateman A., Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am. J. Psychiatry. 2009; 166(12): 1355 - 1364.

12. Bateman A., Fonagy P. Personality Disorders: Theory, Research and Treatment A Randomized Controlled Trial of a Mentalization-Based Borderline Personality Disorder A Randomized Controlled Trial of a Mentalization-Based Intervention (MBT-FACTS) for Families of People With. 2019; 10(1): 70.

13. Moller C., Kalgren L., Sandell A., Falkenstrom F., Philips B. Mentalization-based therapy adherence and competence stimulates in-session mentalization in psychotherapy for borderline personality disorder with co-morbid substance dependence. Trials. 2016/07/14 ed. 2017; 27(6): 749 - 765.

14. Philips B, Wennberg P, Konradsson P, Franck J. Mentalization-Based Treatment for Concurrent Borderline Personality Disorder and Substance Use Disorder: A Randomized Controlled Feasibility Study. Eur Addict Res. 2018/02/07 ed. 2018; 24(1): 1 - 8.

15. Kvarstein EH, Pedersen G, Folmo E, Urnes 0, Johansen MS, Hummelen B, et al. Mentalization-based treatment or psychodynamic treatment programmes for patients with borderline personality disorder - the impact of clinical severity. Psychol Psychother Theory Res Pract. 2018. 1 - 21.

16. Бурно А.А. Практическое руководство по Терапии творческим самовыражением/Под. ред. М.Е. Бурно, Е.А. Добролюбовой. - М.: Академический Проект, ОППЛ, 2003. - С. 342 - 347.

17. Бурно М.Е. Клиническая психотерапия. Изд. 2-е, доп. и перераб. - М.:

18. Академический проект; Деловая книга, 2006;

19. Иговская А.С. Краткая история клинической психотерапии пациентов со специфическими расстройствами личности с преобладанием ипохондрии//Мед. психология в России. 2012. N 2 (13). - С. 1 - 4.

20. Кернберг О.Ф. Тяжелые личностные расстройства. Стратегии психотерапии. Severe Personality Disorders: Psychotherapeutic Strategies. - Москва: Независимая фирма "Класс", 2001. - 464 с.

21. Stoffers JM, Vollm BA, Rucker G et al. Pharmacological intervention for borderline personality disorder. Cochrane Database Syst Rev 2010.

22. Ingenhoven T., Lafay P., Rinne T. et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials//J. Clin. Psychiatry. 2010. Vol. 71. P. 14 - 25.

23. Смулевич А.Б. Расстройства личности. Траектория в пространстве психической и соматической патологии. - М.: МИА, 2012. - 336 с.

24. Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Moller HJ; WFSBP Task Force on Personality Disorders; World Federation of Societies of Biological Psychiatry (WFSBP). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry. 2007; 8(4): 212 - 44.

25. Арана Дж., Розенбаум Дж. Фармакотерапия психических расстройств. Пер. с англ. М.: "Издательство БИНОМ", 2006. - 416 с.

26. Stahl S.M. Stahl"s essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press, 2013.

27. Alapin B., Stanczak T. Neuleptil (propericiazine) - a correcting drug in behavior disorders. Preliminary report (article in Polish). Neurologia, Neurochirurgiai Psychiatria Polska 1966; 16 (10): 1167 - 1171;

28. Daneel A.B. Neulactil (pericyazine) in the behaviour disturbances of institutionalized mental defectives. SAJ Med Sci 1967; 41 (39): 995 - 998;

29. Nardini L, Pistoni A. Selectivity of action of propericiazine in behavior disorders (article in Italian). Rivista Sperimentale Freniatria Medicina Legale Alienazioni Mentali. 1967; 91 (2): 569 - 575;

30. Nimb M. Proceedings of a symposium on behavioural disorders held in Leeds. Ed. F.A. Jenner. Dagenham, 1965; p. 21;

31. Rasch P.J. Treatment of disorders of character and schizophrenia by pericyazine (Neulactil). Acta Psychiatr Scand. (Suppl.) 1966; 191: 200 - 215;

32. Villa J.L., Nouri A. Therapy of personality problems and behavior in the aged with a phenothiazine derivative (neuleptil) (article in French). Praxis 1967; 56 (44): 1500 - 1510;

33. Volmat R. Proceedings of a symposium on behavioural disorders held in Leeds. Ed. F.A. Jenner. Dagenham, 1965; p. 30; Wallis GG. Proceedings of a symposium on behavioural disorders held in Leeds. Ed. F.A. Jenner. Dagenham, 1965; p. 26;

34. Ionescu R, Nica S.U., Oproiu L. et al. Double-blind study in psychopathic behavior disorders (clozapine and pericyazine). Pharmakopsychiatrie Neuropsychopharmakologie 1973; 6 (6): 294 - 9,

35. Калинин В.В. Неулептил: применение в клинической практике. Социальная и клиническая психиатрия. 1993; 3(3): 134 - 138.

36. Данилов Д.С. Эффективность и переносимость терапии перициазином больных шизотипическим расстройством, органическим расстройством личности и пациентов с патохарактерологическими нарушениями в рамках расстройств личности. Журн. неврологии и психиатрии им. С.С. Корсакова. 2017; 117 (10): 65 - 71.

37. Soloff P.H., Cornelius J., George A., Nathan S., Perel J.M., Ulrich R.F.: Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50: 377 - 385.

38. Duivenvoorden H. J. Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains//Journal of clinical psychopharmacology. - 2011. - Т. 31. - N. 4. - С. 489 - 496.

39. Cornelius J.R., Soloff P.H., Perel J.M., Ulrich R.F.: Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry 1993; 150: 1843 - 1848.

40. Nose M. et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials//International clinical psychopharmacology. - 2006. - Т. 21. - N. 6. - С. 345 - 353.

41. Vita A., De Peri L., Sacchetti E. Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials//Journal of Clinical Psychopharmacology. - 2011. - Т. 31. - N. 5. - С. 613 - 624.

42. Tang T.Z., DeRubeis R.J., Hollon S.D. et al. Personality change during depression treatment: a placebo-controlled trial//Arch. Gen. Psychiatry. 2009. Vol. 66. P. 1322 - 1330.

43. Salzmann C., Wolfson A.N., Schatzberg A., et al. 1995. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 15: 23 - 29.

44. Coccaro E.F., Kavoussi R.J. 1997. Fluoxetine and impulsive aggressive behaviour in personality-disordered subjects. Arch Gen Psychiatry 54: 1081 - 1088.

45. Fan A.H., Hassell J. Bipolar disorder and comorbid personality psychopathology: a review of the literature to examine the prevalence of personality disorder comorbidity in bipolar disorder and examine the effects of this comorbidity on bipolar disorder patients//J. Clin. Psychiatry. 2008. Vol. 69, N 11. P. 1794 - 803.

46. Zanarini M.C., Frankenburg F.R., Parachini E.A. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004; 65: 903 - 907.

47. Ekselius L., von Knorring L. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram//Int. Clin. Psychopharmacol. 1998. Vol. 13, N 5. P. 205 - 211.

48. Soloff P.H., George A., Nathan S., Schulz P.M., Cornelius J.R., Herring J., Perel J.M.: Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989; 9: 238 - 246;

49. Feske U, Mulsant BH, Pilkonis PA, et al. Clinical outcome of ECT in patients with major depression and comorbid borderline personality disorder//Am J Psychiatry - 2004; 161(11): 2073 - 80.

50. Feffer K, Peters SK, Bhui K, Downar J, Giacobbe P. Successful dorsomedial prefrontal rTMS for major depression in borderline personality disorder: Three cases.//Brain Stimul. 2017 May - Jun; 10(3): 716 - 717.

51. Mohammad A. High frequency TMS for the management of Borderline Personality Disorder: A case report//Asian Journal of Psychiatry - 2013, 6: 614 - 617.

52. Reyes-Lopez J. et al. Clinical improvement in patients with borderline personality disorder after treatment with repetitive transcranial magnetic stimulation: preliminary results Revista Brasileira de Psiquiatria.//Brazilian Journal of Psychiatry - 2018; 40: 97 - 104.

53. Мосолов С.Н., Цукарзи Э.Э., Маслеников Н.В. Применение транскраниальной магнитной стимуляции в психиатрии/под ред. С.Н. Мосолова/- Иваново: Нейрософт, 2023, 576 с.

54. Prosser A., Helfer B., Leucht S. Biological v. psychosocial treatment: a myth about pharmacotherapy v. psychotherapy//Br. J. Psychiatr. 2016. Vol. 208. P. 209 - 211.

55. McLaughlin S. P. B. et al. Group psychotherapy for borderline personality disorder: A meta-analysis of randomized-controlled trials//Psychotherapy. - 2019. - Т. 56. - N. 2. - С. 260.

56. Cristea I. A. et al. Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis//Jama psychiatry. - 2017. - Т. 74. - N. 4. - С. 319 - 328.

57. Barnicot K. et al. Treatment completion in psychotherapy for borderline personality disorder - a systematic review and meta-analysis//Acta Psychiatrica Scandinavica. - 2011. - Т. 123. - N. 5. - С. 327 - 338.

58. Kliem S., Kroger C., Kosfelder J. Dialectical behavior therapy for borderline personality disorder: a meta-analysis using mixed-effects modeling//Journal of consulting and clinical psychology. - 2010. - Т. 78. - N. 6. - С. 936.

59. Oud M. et al. Specialized psychotherapies for adults with borderline personality disorder: a systematic review and meta-analysis//Australian & New Zealand Journal of Psychiatry. - 2018. - Т. 52. - N. 10. - С. 949 - 961.

60. Chakhssi F. et al. Effect of psychotherapy for borderline personality disorder on quality of life: a systematic review and meta-analysis//Journal of personality disorders. - 2021. - Т. 35. - N. 2. - С. 255 - 269.

61. Wilson H. A. Can antisocial personality disorder be treated? A meta-analysis examining the effectiveness of treatment in reducing recidivism for individuals diagnosed with ASPD//International Journal of Forensic Mental Health. - 2014. - Т. 13. - N. 1. - С. 36 - 46.

62. Bateman, A. and Fonagy, P. (1999). Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 156: 1563 - 1569;

63. Chiesa, M. and Fonagy, P. (2003). Psychosocial treatment for severe personality disorder: 36-month follow-up. Br J Psychiatry 183: 356 - 362.

64. Spong A. J. et al. Brief psychological interventions for borderline personality disorder. A systematic review and meta-analysis of randomised controlled trials//Clinical psychology review. - 2020. - С. 101 - 937.

65. Gibbon S. et al. Psychological interventions for antisocial personality disorder//Cochrane Database of Systematic Reviews. - 2020. - N. 9.

66. Oltmanns J. R. et al. General factors of psychopathology, personality, and personality disorder: Across domain comparisons//Clinical psychological science. - 2018. - Т. 6. - N. 4. - С. 581 - 589.

67. Derksen J., Sloore H. Psychodiagnostics and Indications for Treatment in Cases of Personality Disorder//Treatment of personality disorders. - Springer, Boston, MA, 1999. - С. 155 - 166.

68. Gamache D. et al. A Proposed Classification of ICD-11 Severity Degrees of Personality Pathology Using the Self and Interpersonal Functioning Scale//Front Psychiatry. 2021. V. 12.

69. Самылкин Д.В., Демидова Л.Ю., Гадисов Т.Г. и др. Предварительная адаптация и валидизация психометрических методик для дименсиональной оценки расстройств личности в рамках перехода к МКБ-11//Российский психиатрический журнал. 2023. N 1. С. 51 - 59.

70. Самылкин Д.В., Демидова Л.Ю., Гадисов Т.Г. и др. Валидность и внутренняя согласованность русскоязычной версии опросника личностного и межличностного функционирования (SIFS)//Российский психиатрический журнал. 2023. N 4. С. 64 - 71.

71. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, VA: American Psychiatric Association, 2013. 943 p.

72. Oltmanns J.R., Widiger T.A. The Five-Factor Personality Inventory for ICD-11: A FacetLevel Assessment of the ICD-11 Trait Model//Psychol Assess. 2020. Vol. 32. N 1. P. 60.

73. Widiger T.A., Simonsen E. Alternative dimensional models of personality disorder: finding a common ground//J Pers Disord. 2005. Vol. 19. N 2. P. 110 - 130.

74. Simonsen S., Bateman A, Bohus M et al, European guidelines for personality disorders: past, present and future. Borderline Personality Disorder and Emotion Dysregulation. 2019; (6)

75. Stoffers-Winterling J, Vollm B, Lieb K. Is pharmacotherapy useful for treating personality disorders? Expert Opin Pharmacother. 2021 Mar; 22(4): 393 - 395

76. Gartlehner G, Crotty K, Kennedy S, Edlund MJ, Ali R, Siddiqui M, Fortman R, Wines R, Persad E, Viswanathan M. Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis. CNS Drugs. 2021 Oct; 35(10): 1053 - 1067.

77. Casale A, Bonanni L, Bargagna P et al. Current Clinical Psychopharmacology in Borderline Personality Disorder. Curr Neuropharmacol. 2021; 19(10): 1760 - 1779.

78. Christea IA, Gentili C, Cotet CD, Palomba D, Barbui C, Cuijpers P. Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2017; 74(4): 319 - 328.

79. McMain SF, Chapman AL, Kuo JR, Dixon-Gordon KL, Guimond TH, Labrish C, Isaranuwatchai W, Streiner DL. The Effectiveness of 6 versus 12 Months of Dialectical Behavior Therapy for Borderline Personality Disorder: A Noninferiority Randomized Clinical Trial. Psychother Psychosom. 2022; 91(6): 382 - 397.

80. Arntz A, Jacob GA, Lee CW, Brand-de Wilde OM, Fassbinder E, Harper RP, Lavender A, Lockwood G, Malogiannis IA, Ruths FA, Schweiger U, Shaw IA, Zarbock G, Farrell JM. Effectiveness of Predominantly Group Schema Therapy and Combined Individual and Group Schema Therapy for Borderline Personality Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022 Apr 1; 79(4): 287 - 299.

81. Iliakis EA, Sonley AKI, Ilagan GS, Choi-Kain LW. Treatment of borderline personality disorder: is supply adequate to meet public health needs? Psychiatr Serv. 2019; 70(9): 772 - 781.

82. Eskander N., Emamy M., Saad-Omer S.M. et al. The Impact of Impulsivity and emotional dysregulation on comorbid bipolar disorder and borderline personality disorder. Cureus. 2020; 12(8): 9581.